Gilenya and Tasigna drive new product growth at Novartis
This article was originally published in Scrip
Novartis's Gilenya (fingolimod) has had an excellent launch, with sales of the product "outpacing all previous launches in multiple sclerosis" according to the firm. The first oral product for relapsing remitting or relapsing MS, approved by the FDA in October 2010 and by the EMA in March 2011, Gilenya posted sales of $79 million in the second quarter and $138 million for the first half of 2011.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.